327 related articles for article (PubMed ID: 31348835)
21. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
22. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
23. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
[TBL] [Abstract][Full Text] [Related]
24. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
25. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M; Micol JB; Duployez N; Raffoux E; Thomas X; Marolleau JP; Braun T; Adès L; Chantepie S; Lemasle E; Berthon C; Malfuson JV; Pautas C; Lambert J; Boissel N; Celli-Lebras K; Caillot D; Turlure P; Vey N; Pigneux A; Recher C; Terré C; Gardin C; Itzykson R; Preudhomme C; Dombret H; de Botton S
Blood; 2021 May; 137(20):2827-2837. PubMed ID: 33881523
[TBL] [Abstract][Full Text] [Related]
29. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
30. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Kayser S; Döhner K; Krauter J; Köhne CH; Horst HA; Held G; von Lilienfeld-Toal M; Wilhelm S; Kündgen A; Götze K; Rummel M; Nachbaur D; Schlegelberger B; Göhring G; Späth D; Morlok C; Zucknick M; Ganser A; Döhner H; Schlenk RF;
Blood; 2011 Feb; 117(7):2137-45. PubMed ID: 21127174
[TBL] [Abstract][Full Text] [Related]
31. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
32. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
33. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
34. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
35. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
36. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
[TBL] [Abstract][Full Text] [Related]
39. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
40. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
